Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active Bone Marrow Protection ± Pegylated G-CSF for Prevention of Neutropenia in Concurrent Chemoradiotherapy for Cervical Cancer
ChiCTR2400087321Phase 3Not yet recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pegfilgrastim in Cervical Cancer (CC) and chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Yibin Second People's Hospital. Primary endpoint: Neutropenia. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
Cervical Cancer (CC)chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR2400087321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087321.